Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Teva Pharmaceutical Industries Ltd.

https://www.tevapharm.com/

Latest From Teva Pharmaceutical Industries Ltd.

Teva Inks $450m Deals Over US Kickback Claims, Including Alleged Copay Violations

Bookmark
  • News
By Dean Rudge

Teva resolved two US Department of Justice civil suits accusing the firm of violating the US Anti-Kickback Statute and the False Claims Act by allegedly conspiring to fix the price of three generic drugs and paying Medicare patients’ copays for its multiple sclerosis brand product Copaxone.

Legal Issues Reimbursement

Teva Inks $450m Deals Over US Kickback Claims, Including For Generic Price-Fixing

Bookmark
  • News
By Dean Rudge

Teva has resolved a pair of civil US Department of Justice lawsuits accusing the firm of violating the US Anti-Kickback Statute and the False Claims Act through its alleged conduct conspiring to fix the price of three generic drugs and for allegedly paying Medicare patients’ copays for its multiple sclerosis brand Copaxone.

Deals Enforcement

Sandoz, Adalvo And Eurofarma Celebrate Multiple Wins At GGB Awards

Bookmark
  • News
By David Wallace

Sandoz, Adalvo and Eurofarma were the biggest winners at the Global Generics & Biosimilars Awards 2024, each taking multiple honors, among the many champions named across 14 separate categories at our prizegiving ceremony in Milan.

Generic Drugs Biosimilars

Teva Files For Prolia Biosimilar In The US And Europe – But Not Xgeva

Bookmark
  • News
By Dean Rudge

Teva has broken new ground by filing its first independent biosimilar to the US Food and Drug Administration, for a proposed biosimilar to Amgen’s Prolia treatment for osteoporosis in postmenopausal women. However, the Israeli firm made no mention of its proposed Xgeva biosimilar, which it states is in Phase III clinical trials.

Drug Review Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • ABIC Marketing Limited
    • AbZ-Pharma
    • Auspex Pharmaceuticals, Inc. (Imphar AG)
    • Barr Pharmaceuticals
    • Bentley Pharmaceuticals
    • BioGeneriX AG
    • BioAssets Development Corporation
    • Cephalon, Inc. (Arana Therapeutics (Peptech and EvoGenix)
    • Ception Therapeutics
    • ChemGenex Pharmaceuticals Limited
    • CIMA Labs
    • Gemin X Pharmaceuticals
    • CT Arzneimittel GmbH
    • Gecko Health Innovations
    • IVAX Corporation
    • Labrys Biologics
    • Mepha
    • MicroDose Therapeutx Inc.
    • Neose Technologies, Inc.
    • NuPathe, Inc.
    • PLIVA HRVATSKA d.o.o.
    • ratiopharm Group
    • Sicor Biotech
    • Representaciones e Investigaciones Médicas, S.A. de C.V.
    • Taiyo Pharmaceutical Industry Co. Ltd.
    • Teva Branded Pharmaceutical Products, R&D Inc.
    • Teva Women's Health, Inc.
    • Actavis Generics
    • Anda, Inc.
    • Uteron Pharma S.P.R.L.
    • Teva Takeda Yakuhin Ltd.
    • Teva Takeda Pharma Ltd.
    • Teva Neuroscience, Inc.
    • Teva Pharmaceuticals USA, Inc.
    • Zeneus Pharma
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By